1591366604.png)
Research News
Keeping current on all preeclampsia research
A new diagnostic test for preeclampsia has received approval from the US Food and Drug Administration for use in hospital settings.
A new research study published out of the UK in April 2023 in Hypertension found that more than half of all preeclampsia cases which occur during weeks 37-42 of pregnancy (“at-term”) may be prevented with timed birth. Screening for preec...
Based on limited data, pravastatin use during pregnancy does not appear to have any long-term adverse effects on children. his information will be useful for gaining approval for larger studies to see if pravastatin is actually useful in preventing...
In this paper, researchers describe how they developed an ionized lipid nanoparticle that is taken into mouse placental cells to increase VEGF.
Identifying the healthful behaviors that lower the risk for a hypertensive disorder of pregnancy can help develop recommendations and prevention programs to support lowering pregnant women’s risk for developing a hypertensive disorder of pregnancy.
Genetic research over the past 10 years has shown a difference in gene expression in single-cells from placentas of pregnancies with preeclampsia compared to normotensive placentas.
Researchers asked if microRNAs that are linked to cardiovascular disease in non-pregnant people could help predict HELLP syndrome.
Researchers have found several maternal nutritional and dietary factors that may increase or decrease the risk of developing preeclampsia, though the association between the two is complex.
What you’ll learn in this article: Many risk factors contribute to an individual’s chance of getting preeclampsia. These risk factors may be genetic, physical, environmental, and even social. Don’t blame yourself for developing...
Preeclampsia Foundation Canada announced today at the Society for Maternal-Fetal Medicine’s (SMFM) 43rd Annual Meeting – The Pregnancy Meeting™ – that applications are now being accepted for its 2023 Vision Grant program.
The study is designed to potentially accelerate discovery of therapies for preeclampsia by designing placental cell lines that express variants of the APOL1 gene for drug screening.
This study suggests that women of different BMI classes might have distinct risk profiles for preeclampsia.